Social Europe

  • EU Forward Project
  • YouTube
  • Podcast
  • Books
  • Newsletter
  • Membership

How to develop a Covid-19 vaccine for all

Mariana Mazzucato and Els Torreele 29th April 2020

Ensuring no one is left behind requires not just unprecedented collective investment but a very different approach to innovation.

Covid-19 vaccine
Mariana Mazzucato

In the early weeks of 2020, it started to dawn on people that Covid-19 could be the long-dreaded but expected ‘Disease X’—a global pandemic caused by an unknown virus. Three months later, the majority of the world’s population is in lockdown, and it is clear that we are only as healthy as our neighbours—locally, nationally and internationally.

Strong health systems, adequate testing capacity and an effective, universally available vaccine will be key to protecting societies from Covid-19. But ensuring that no one is left behind requires not just unprecedented collective investment, but also a very different approach.

Covid-19 vaccine
Els Torreele

Researchers at universities and companies around the world are racing to develop a vaccine. And current progress is encouraging: 73 vaccine candidates are actively being explored or are in preclinical development, while five already have entered clinical trials.

Public investment

These massive efforts are possible only because of substantial public investment, including by the US National Institutes of Health and the Coalition for Epidemic Preparedness Innovations (CEPI). The latter, a publicly funded non-profit organisation, was established after the 2014-16 west-African Ebola epidemic to drive research and development of vaccines that could be deployed during disease outbreaks.

CEPI has so far received an extra $765 million of a targeted $2 billion in funding for Covid-19 vaccine development from multiple governments. The Biomedical Advanced Research and Development Authority, part of the US Department of Health and Human Services, has invested substantially in vaccine-development projects with Johnson & Johnson ($450 million) and Moderna ($483 million). And the European Union intends to mobilise further public funding to tackle the pandemic at an online pledging conference on May 4th.

But investment alone is not enough. To succeed, the entire vaccine-innovation process, from research and development to access, must be governed by clear and transparent rules of engagement based on public-interest goals and metrics. That, in turn, will require a clear alignment between global and national public interests.

Mission-oriented approach

The first, critical step is to adopt a mission-oriented approach that focuses both public and private investments on achieving a clearly defined common goal: developing an effective Covid-19 vaccine(s) that can be produced at global scale rapidly and made universally available for free. Realizing this aim will require firm rules regarding intellectual property (IP), pricing and manufacturing, designed and enforced in ways that value international collaboration and solidarity, rather than competition between countries.

Secondly, to maximise the impact on public health, the innovation ecosystem must be steered to use collective intelligence to accelerate advances. Science and medical innovation thrives and progresses when researchers exchange and share knowledge openly, enabling them to build upon one another’s successes and failures in real time.

But today’s proprietary science does not follow that model. Instead, it promotes secretive competition, prioritises regulatory approval in wealthy countries over wide availability and global public-health impact, and erects barriers to technological diffusion. And, although voluntary intellectual-property pools like the one that Costa Rica has proposed to the World Health Organization can be helpful, they risk being ineffective as long as private, for-profit companies are allowed to retain control over critical technologies and data—even when these were generated with public investments.

Moreover, collective steering is vital to select and pursue the most promising potential vaccines. Otherwise, marketing authorisation may go to the best-resourced candidate rather than the most suitable one.

Capacity and infrastructure

Thirdly, countries must take the lead in building and buttressing manufacturing capabilities, particularly in the developing world. While an effective Covid-19 vaccine probably will not be available for another 12-18 months, a concerted effort is needed now to put in place the public and private capacity and infrastructure needed to produce rapidly the billions of doses that will be required.

Because we don’t know yet which vaccine will prove most effective, we may need to invest in a range of assets and technologies. This poses a technological and financial risk that can be overcome only with the help of entrepreneurial states backed by collective, public-interest-driven financing, such as from national and regional development banks, the World Bank and philanthropic foundations.

Finally, conditions for ensuring global, equitable and affordable access must be built into any vaccine-development programme from the start. This would allow public investments to be structured less like a handout or simple market-fixer, and more like a proactive market-shaper, driven by public objectives.

Pricing of Covid-19 vaccines should reflect both the substantial public contribution to their development and the urgency and magnitude of the global health crisis. We must go beyond statements of principle and generic pledges, and introduce concrete conditions that enable vaccines to be free at the point of use. Policy-makers should also consider using compulsory licensing to allow countries to make the best use of the available tools and technologies.

Crucially, we need collective procurement mechanisms that ensure fair allocation and equitable global access to the new vaccines as they become available. The overriding goal must be to prevent advanced economies from monopolising the global supply or crowding out demand from poorer countries.

Public interest

The Covid-19 crisis rules out a business-as-usual approach. As countries mobilise collectively against the pandemic through calls for a global alliance, pledging conferences, G20 meetings and the upcoming annual World Health Assembly, we cannot afford to miss this chance. These collective efforts must include clear and enforceable rules of engagement that commit all partners to an end-to-end approach to health innovation based on the public interest—an effective Covid-19 vaccine that can be rapidly made available to all for free.

Developing an effective and universally available Covid-19 vaccine is one of the most critical missions of our lifetime. Above all, it is a litmus test of whether global public-private co-operation, touted by policy-makers as the key to success, will maximise the supply of public goods or the share of private profits.

Republication forbidden—copyright Project Syndicate 2020, ‘How to develop a Covid-19 vaccine for all’

Mariana Mazzucato and Els Torreele

Mariana Mazzucato is professor of the economics of innovation and public value and director of the University College London Institute for Innovation and Public Purpose (IIPP); she is author of The Value of Everything: Making and Taking in the Global Economy (Allen Lane, 2019). Els Torreele is executive director of the Médecins Sans Frontières Access Campaign.

Harvard University Press Advertisement

Social Europe Ad - Promoting European social policies

We need your help.

Support Social Europe for less than €5 per month and help keep our content freely accessible to everyone. Your support empowers independent publishing and drives the conversations that matter. Thank you very much!

Social Europe Membership

Click here to become a member

Most Recent Articles

u4219834664e04a 8a1e 4ee0 a6f9 bbc30a79d0b1 2 Closing the Chasm: Central and Eastern Europe’s Continued Minimum Wage ClimbCarlos Vacas-Soriano and Christine Aumayr-Pintar
u421983467f bb39 37d5862ca0d5 0 Ending Britain’s “Brief Encounter” with BrexitStefan Stern
u421983485 2 The Future of American Soft PowerJoseph S. Nye
u4219834676d582029 038f 486a 8c2b fe32db91c9b0 2 Trump Can’t Kill the Boom: Why the US Economy Will Roar Despite HimNouriel Roubini
u42198346fb0de2b847 0 How the Billionaire Boom Is Fueling Inequality—and Threatening DemocracyFernanda Balata and Sebastian Mang

Most Popular Articles

startupsgovernment e1744799195663 Governments Are Not StartupsMariana Mazzucato
u421986cbef 2549 4e0c b6c4 b5bb01362b52 0 American SuicideJoschka Fischer
u42198346769d6584 1580 41fe 8c7d 3b9398aa5ec5 1 Why Trump Keeps Winning: The Truth No One AdmitsBo Rothstein
u421983467 a350a084 b098 4970 9834 739dc11b73a5 1 America Is About to Become the Next BrexitJ Bradford DeLong
u4219834676ba1b3a2 b4e1 4c79 960b 6770c60533fa 1 The End of the ‘West’ and Europe’s FutureGuillaume Duval
u421983462e c2ec 4dd2 90a4 b9cfb6856465 1 The Transatlantic Alliance Is Dying—What Comes Next for Europe?Frank Hoffer
u421983467 2a24 4c75 9482 03c99ea44770 3 Trump’s Trade War Tears North America Apart – Could Canada and Mexico Turn to Europe?Malcolm Fairbrother
u4219834676e2a479 85e9 435a bf3f 59c90bfe6225 3 Why Good Business Leaders Tune Out the Trump Noise and Stay FocusedStefan Stern
u42198346 4ba7 b898 27a9d72779f7 1 Confronting the Pandemic’s Toxic Political LegacyJan-Werner Müller
u4219834676574c9 df78 4d38 939b 929d7aea0c20 2 The End of Progess? The Dire Consequences of Trump’s ReturnJoseph Stiglitz

KU Leuven advertisement

The Politics of Unpaid Work

This new book published by Oxford University Press presents the findings of the multiannual ERC research project “Researching Precariousness Across the Paid/Unpaid Work Continuum”,
led by Valeria Pulignano (KU Leuven), which are very important for the prospects of a more equal Europe.

Unpaid labour is no longer limited to the home or volunteer work. It infiltrates paid jobs, eroding rights and deepening inequality. From freelancers’ extra hours to care workers’ unpaid duties, it sustains precarity and fuels inequity. This book exposes the hidden forces behind unpaid labour and calls for systemic change to confront this pressing issue.

DOWNLOAD HERE FOR FREE

ETUI advertisement

HESA Magazine Cover

What kind of impact is artificial intelligence (AI) having, or likely to have, on the way we work and the conditions we work under? Discover the latest issue of HesaMag, the ETUI’s health and safety magazine, which considers this question from many angles.

DOWNLOAD HERE

Eurofound advertisement

Ageing workforce
How are minimum wage levels changing in Europe?

In a new Eurofound Talks podcast episode, host Mary McCaughey speaks with Eurofound expert Carlos Vacas Soriano about recent changes to minimum wages in Europe and their implications.

Listeners can delve into the intricacies of Europe's minimum wage dynamics and the driving factors behind these shifts. The conversation also highlights the broader effects of minimum wage changes on income inequality and gender equality.

Listen to the episode for free. Also make sure to subscribe to Eurofound Talks so you don’t miss an episode!

LISTEN NOW

Foundation for European Progressive Studies Advertisement

Spring Issues

The Spring issue of The Progressive Post is out!


Since President Trump’s inauguration, the US – hitherto the cornerstone of Western security – is destabilising the world order it helped to build. The US security umbrella is apparently closing on Europe, Ukraine finds itself less and less protected, and the traditional defender of free trade is now shutting the door to foreign goods, sending stock markets on a rollercoaster. How will the European Union respond to this dramatic landscape change? .


Among this issue’s highlights, we discuss European defence strategies, assess how the US president's recent announcements will impact international trade and explore the risks  and opportunities that algorithms pose for workers.


READ THE MAGAZINE

Hans Böckler Stiftung Advertisement

WSI Report

WSI Minimum Wage Report 2025

The trend towards significant nominal minimum wage increases is continuing this year. In view of falling inflation rates, this translates into a sizeable increase in purchasing power for minimum wage earners in most European countries. The background to this is the implementation of the European Minimum Wage Directive, which has led to a reorientation of minimum wage policy in many countries and is thus boosting the dynamics of minimum wages. Most EU countries are now following the reference values for adequate minimum wages enshrined in the directive, which are 60% of the median wage or 50 % of the average wage. However, for Germany, a structural increase is still necessary to make progress towards an adequate minimum wage.

DOWNLOAD HERE

Social Europe

Our Mission

Team

Article Submission

Advertisements

Membership

Social Europe Archives

Themes Archive

Politics Archive

Economy Archive

Society Archive

Ecology Archive

Miscellaneous

RSS Feed

Legal Disclosure

Privacy Policy

Copyright

Social Europe ISSN 2628-7641